JP2004518725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518725A5 JP2004518725A5 JP2002564509A JP2002564509A JP2004518725A5 JP 2004518725 A5 JP2004518725 A5 JP 2004518725A5 JP 2002564509 A JP2002564509 A JP 2002564509A JP 2002564509 A JP2002564509 A JP 2002564509A JP 2004518725 A5 JP2004518725 A5 JP 2004518725A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydrogen
- aryl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 160
- 229910052739 hydrogen Inorganic materials 0.000 description 113
- 125000003118 aryl group Chemical group 0.000 description 111
- 239000001257 hydrogen Substances 0.000 description 96
- 125000005843 halogen group Chemical group 0.000 description 80
- 125000001424 substituent group Chemical group 0.000 description 70
- 150000002431 hydrogen Chemical class 0.000 description 60
- 125000001072 heteroaryl group Chemical group 0.000 description 53
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 28
- -1 piperazine compound Chemical class 0.000 description 26
- 125000003342 alkenyl group Chemical group 0.000 description 24
- 125000000304 alkynyl group Chemical group 0.000 description 23
- 229910052799 carbon Inorganic materials 0.000 description 22
- 125000004122 cyclic group Chemical group 0.000 description 17
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000004663 dialkyl amino group Chemical group 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 5
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYTNTASXQAZPTK-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-[(2-methyl-1,3-benzothiazol-5-yl)oxy]propyl]piperazin-1-yl]-n-(4-hydroxyphenyl)acetamide Chemical compound C=1C=C2SC(C)=NC2=CC=1OCC(O)CN(CC1)CCN1CC(=O)NC1=CC=C(O)C=C1 RYTNTASXQAZPTK-UHFFFAOYSA-N 0.000 description 1
- KNRLWMVXYOQGFW-UHFFFAOYSA-N 2-[4-[3-(1,3-benzothiazol-2-ylamino)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)CNC=2SC3=CC=CC=C3N=2)CC1 KNRLWMVXYOQGFW-UHFFFAOYSA-N 0.000 description 1
- QJOYTGCZTPWACL-UHFFFAOYSA-N 2-[4-[3-(1,3-benzothiazol-2-yloxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2SC3=CC=CC=C3N=2)CC1 QJOYTGCZTPWACL-UHFFFAOYSA-N 0.000 description 1
- VOBBYHJBAIAYRU-UHFFFAOYSA-N 2-[4-[3-(1,3-benzothiazol-6-yloxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C=C3SC=NC3=CC=2)CC1 VOBBYHJBAIAYRU-UHFFFAOYSA-N 0.000 description 1
- ZHRAGUPUYMHBFK-UHFFFAOYSA-N 4-[3-[4-[2-(2,6-dimethylanilino)-2-oxoethyl]piperazin-1-yl]-2-hydroxypropoxy]-1h-indole-2-carboxamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C=3C=C(NC=3C=CC=2)C(N)=O)CC1 ZHRAGUPUYMHBFK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- PANDQMJLXMUMDT-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-(2-hydroxy-3-isoquinolin-5-yloxypropyl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C3=CC=NC=C3C=CC=2)CC1 PANDQMJLXMUMDT-UHFFFAOYSA-N 0.000 description 1
- OPOHBZPGKPHACY-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-(2-hydroxy-3-pyridin-3-yloxypropyl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C=NC=CC=2)CC1 OPOHBZPGKPHACY-UHFFFAOYSA-N 0.000 description 1
- BLZSDWMDBCVLPR-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-(2-hydroxy-3-quinolin-4-yloxypropyl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C3=CC=CC=C3N=CC=2)CC1 BLZSDWMDBCVLPR-UHFFFAOYSA-N 0.000 description 1
- GLOMJZJUNGBQGT-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-(2-hydroxy-3-quinoxalin-2-yloxypropyl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2N=C3C=CC=CC3=NC=2)CC1 GLOMJZJUNGBQGT-UHFFFAOYSA-N 0.000 description 1
- BIRCHGVQTHMZMO-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methylquinolin-7-yl)oxypropyl]piperazin-1-yl]acetamide Chemical compound C=1C2=NC(C)=CC=C2C=CC=1OCC(O)CN(CC1)CCN1CC(=O)NC1=C(C)C=CC=C1C BIRCHGVQTHMZMO-UHFFFAOYSA-N 0.000 description 1
- ZSJQEOXCZMMJFS-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-[(2-methyl-1,3-benzothiazol-5-yl)oxy]propyl]-2-oxopiperazin-1-yl]acetamide Chemical compound C=1C=C2SC(C)=NC2=CC=1OCC(O)CN(CC1=O)CCN1CC(=O)NC1=C(C)C=CC=C1C ZSJQEOXCZMMJFS-UHFFFAOYSA-N 0.000 description 1
- HWCAHWFWTGNIBN-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-[(2-methyl-1,3-benzoxazol-5-yl)oxy]propyl]piperazin-1-yl]acetamide Chemical compound C=1C=C2OC(C)=NC2=CC=1OCC(O)CN(CC1)CCN1CC(=O)NC1=C(C)C=CC=C1C HWCAHWFWTGNIBN-UHFFFAOYSA-N 0.000 description 1
- TXYVYXLNUPKJEV-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-[(2-phenyl-1,3-benzothiazol-5-yl)oxy]propyl]piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C=C3N=C(SC3=CC=2)C=2C=CC=CC=2)CC1 TXYVYXLNUPKJEV-UHFFFAOYSA-N 0.000 description 1
- OULDEVLLHJFRPR-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-[(2-phenyl-1,3-benzoxazol-5-yl)oxy]propyl]piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C=C3N=C(OC3=CC=2)C=2C=CC=CC=2)CC1 OULDEVLLHJFRPR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/694,155 US6573264B1 (en) | 2000-10-23 | 2000-10-23 | Heteroaryl alkyl piperazine derivatives |
| PCT/US2001/051032 WO2002064576A1 (en) | 2000-10-23 | 2001-10-19 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004518725A JP2004518725A (ja) | 2004-06-24 |
| JP2004518725A5 true JP2004518725A5 (https=) | 2008-05-15 |
| JP4138489B2 JP4138489B2 (ja) | 2008-08-27 |
Family
ID=24787627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564509A Expired - Fee Related JP4138489B2 (ja) | 2000-10-23 | 2001-10-19 | 脂肪酸の酸化防止剤としてのヘテロアリールアルキルピペラジン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US6573264B1 (https=) |
| EP (1) | EP1339701B1 (https=) |
| JP (1) | JP4138489B2 (https=) |
| KR (1) | KR20030044029A (https=) |
| CN (1) | CN1303074C (https=) |
| AR (1) | AR034173A1 (https=) |
| AT (1) | ATE353882T1 (https=) |
| AU (1) | AU2002255466B2 (https=) |
| CA (1) | CA2426535A1 (https=) |
| DE (1) | DE60126643T2 (https=) |
| ES (1) | ES2279790T3 (https=) |
| HU (1) | HUP0303552A3 (https=) |
| IL (2) | IL155294A0 (https=) |
| MX (1) | MXPA03003531A (https=) |
| NO (2) | NO20031784L (https=) |
| NZ (1) | NZ525259A (https=) |
| PL (1) | PL362004A1 (https=) |
| PT (1) | PT1339701E (https=) |
| RU (1) | RU2243970C1 (https=) |
| SI (1) | SI1339701T1 (https=) |
| TW (1) | TWI286135B (https=) |
| WO (1) | WO2002064576A1 (https=) |
| ZA (1) | ZA200302990B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| US7001909B2 (en) * | 2001-07-19 | 2006-02-21 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| WO2003008411A1 (en) * | 2001-07-19 | 2003-01-30 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US7056924B2 (en) * | 2002-07-18 | 2006-06-06 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| TW200504033A (en) * | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| EP1806346B1 (en) * | 2002-12-05 | 2009-07-22 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| AU2003300827B2 (en) * | 2002-12-05 | 2009-08-13 | Gilead Palo Alto, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| NZ541069A (en) * | 2003-01-03 | 2008-09-26 | Cv Therapeutics Inc | Piperazine derivatives as fatty acid oxidation inhibitors |
| CA2511970C (en) * | 2003-01-14 | 2012-06-26 | Cytokinetics, Inc. | Urea derivatives useful in the treatment of heart failure |
| NZ541306A (en) * | 2003-01-17 | 2008-07-31 | Cv Therapeutics Inc | Substituted piperazine and piperidine derivatives useful in the treatment of cardiovascular diseases |
| NZ544449A (en) * | 2003-06-23 | 2008-10-31 | Cv Therapeutics Inc | Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| EP1723129A1 (en) * | 2003-12-18 | 2006-11-22 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| US7163944B2 (en) * | 2004-01-26 | 2007-01-16 | Kowa Co., Ltd. | Cyclic diamine compound and pharmaceutical containing the same |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| WO2006029179A2 (en) * | 2004-09-08 | 2006-03-16 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| US20060074105A1 (en) * | 2004-09-20 | 2006-04-06 | Serenex, Inc. | Substituted quinoline and quinazoline inhibitors of quinone reductase 2 |
| US20060205727A1 (en) * | 2005-03-11 | 2006-09-14 | Wayne Kaesemeyer | Combination therapy for endothelial dysfunction, angina and diabetes |
| US7538223B2 (en) * | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US20070197505A1 (en) * | 2005-12-15 | 2007-08-23 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP1962852B1 (en) * | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007079003A2 (en) * | 2005-12-29 | 2007-07-12 | Bayer Schering Pharma Aktiengesellschaft | Amide inhibitors of leukotriene a4 hydrolase |
| US8389500B2 (en) * | 2008-10-30 | 2013-03-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｎｓ障害の治療のためのラノラジン |
| EP2621490A4 (en) * | 2010-09-29 | 2014-04-02 | Teva Pharma | PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF |
| HUE056957T2 (hu) * | 2014-08-29 | 2022-04-28 | Chdi Foundation Inc | Próbák huntingtin fehérjét megjelenítõ képalkotásra |
| EP4092013A1 (en) | 2017-06-20 | 2022-11-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| WO2020081361A1 (en) | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| RU2751878C2 (ru) * | 2018-12-06 | 2021-07-19 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | 1-(Метоксибензил)-4-[2-((метоксибензил)амино)этил]пиперазины, обладающие антиаритмической активностью |
| WO2020243120A1 (en) | 2019-05-31 | 2020-12-03 | Imbria Pharmaceuticals, Inc. | Methods of treating fibrosis using compounds that promote glucose oxidation |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| CN114805112A (zh) * | 2022-05-31 | 2022-07-29 | 常州大学 | 一种pde2抑制剂酰胺类衍生物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| ATE142497T1 (de) | 1989-06-23 | 1996-09-15 | Syntex Inc | Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen |
| WO1991007967A2 (en) * | 1989-11-22 | 1991-06-13 | Janssen Pharmaceutica N.V. | Method of preventing or limiting reperfusion damage |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| AU2001238590A1 (en) | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
-
2000
- 2000-10-23 US US09/694,155 patent/US6573264B1/en not_active Expired - Fee Related
-
2001
- 2001-10-19 MX MXPA03003531A patent/MXPA03003531A/es active IP Right Grant
- 2001-10-19 SI SI200130708T patent/SI1339701T1/sl unknown
- 2001-10-19 WO PCT/US2001/051032 patent/WO2002064576A1/en not_active Ceased
- 2001-10-19 RU RU2003115351/04A patent/RU2243970C1/ru not_active IP Right Cessation
- 2001-10-19 EP EP01271075A patent/EP1339701B1/en not_active Expired - Lifetime
- 2001-10-19 CN CNB018177700A patent/CN1303074C/zh not_active Expired - Fee Related
- 2001-10-19 PT PT01271075T patent/PT1339701E/pt unknown
- 2001-10-19 CA CA002426535A patent/CA2426535A1/en not_active Abandoned
- 2001-10-19 ES ES01271075T patent/ES2279790T3/es not_active Expired - Lifetime
- 2001-10-19 AU AU2002255466A patent/AU2002255466B2/en not_active Ceased
- 2001-10-19 DE DE60126643T patent/DE60126643T2/de not_active Expired - Lifetime
- 2001-10-19 AT AT01271075T patent/ATE353882T1/de not_active IP Right Cessation
- 2001-10-19 NZ NZ525259A patent/NZ525259A/en unknown
- 2001-10-19 US US10/398,636 patent/US20040029889A1/en not_active Abandoned
- 2001-10-19 IL IL15529401A patent/IL155294A0/xx active IP Right Grant
- 2001-10-19 PL PL36200401A patent/PL362004A1/xx not_active Application Discontinuation
- 2001-10-19 HU HU0303552A patent/HUP0303552A3/hu unknown
- 2001-10-19 KR KR10-2003-7005645A patent/KR20030044029A/ko not_active Ceased
- 2001-10-19 JP JP2002564509A patent/JP4138489B2/ja not_active Expired - Fee Related
- 2001-10-23 AR ARP010104957A patent/AR034173A1/es unknown
- 2001-10-23 TW TW090126173A patent/TWI286135B/zh not_active IP Right Cessation
-
2002
- 2002-12-05 US US10/313,818 patent/US6849632B2/en not_active Expired - Lifetime
-
2003
- 2003-04-08 IL IL155294A patent/IL155294A/en not_active IP Right Cessation
- 2003-04-16 ZA ZA200302990A patent/ZA200302990B/xx unknown
- 2003-04-22 NO NO20031784A patent/NO20031784L/no unknown
- 2003-04-22 NO NO20031797A patent/NO325220B1/no not_active IP Right Cessation
-
2004
- 2004-03-31 US US10/813,743 patent/US20040192702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518725A5 (https=) | ||
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| RU2003115351A (ru) | Производные гетероарилалкилпиперазина и фармацевтическая композиция на их основе | |
| RU2489148C2 (ru) | Ингибитор активации stat3/5 | |
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| CA2556944A1 (en) | Thiazole derivative | |
| JP2007504160A5 (https=) | ||
| DK5388A (da) | Fremgangsmaade til fremstilling af 2-(4-(diphenylmethyl)-1-piperazinyl)-eddikesyrer eller farmaceutisk acceptable salte heraf | |
| DK1332137T3 (da) | Behandling af gastrointestinale stromale tumorer | |
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| KR850006402A (ko) | 항정신병의 1-플루오로페닐부틸-4-(2-피리미디닐) 피페라진 유도체 | |
| HRP20080226T3 (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JPH10279578A5 (https=) | ||
| JP2006517572A5 (https=) | ||
| KR920701202A (ko) | 헤테로 사이클릭 유도체, 그의 제조방법 및 치료사용 | |
| JP2005539026A5 (https=) | ||
| RU2004119406A (ru) | 5-сульфанил-4н-1,2,4-триазольные производные и их применение в качестве лекарственного препарата | |
| JP2002030084A5 (https=) | ||
| JP2006526596A5 (https=) | ||
| JP2007231005A5 (https=) | ||
| RU2008143232A (ru) | Новый класс ингибиторов гистондеацетилаз | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| RU99100277A (ru) | Производные тиазола | |
| KR840006633A (ko) | 벤족사졸리논 유도체의 제조방법 |